radionuclides

(S)-p-SCN-Bn-DOTA is a bifunctional chelator (Bifunctional Chelator; BFC), serving as a macrocyclic DOTA derivative for tumor pre-targeting. It is utilized for the conjugation of peptides and radionuclides.

3BP-3940, a fibroblast activation protein (FAP)-targeting peptide, serves as a potent agent for theranostics. It is frequently conjugated with radionuclides to facilitate tumor diagnosis and therapy [1].

Edotreotide (SMT-487) is an Indicator and Reagent. It also is used in the Diagnosis and Staging of Tumors Expressing Somatostatin Receptors.

PSMA-D5 exhibits a binding affinity for PSMA with a Ki of 0.21 nM and becomes useful for PSMA tracing following radiolabeling. When marked with [68Ga], PSMA-D5 contains a DOTA chelator, facilitating the convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. Additionally, [68Ga]-labeled PSMA-D5 demonstrates exceptional pharmacokinetic properties and significant tumor uptake in 22Rv1 tumors. This compound can be employed in the synthesis and research of radiolabeled conjugates (RDC).

p-SCN-Bn-DOTA is a chelator that simultaneously binds radionuclides and links monoclonal antibodies. It is utilized as a tracer for radio-guided surgery and serves in radio-immunoassay studies of tumors.

WL12 is a peptide that targets and binds specifically to programmed death ligand 1 (PD-L1). It can be radiolabeled with various radionuclides to produce radiotracers, enabling the evaluation of PD-L1 expression in tumors [1].

NO2A-Butyne is a bifunctional chelator (Bifunctional Chelator; BFC) and a macropolycyclic NOTA derivative utilized in tumor pretargeting. It is suitable for the conjugation of peptides and radionuclides.

DTPA-tetra (t-Bu ester) is a bifunctional chelator (BFC) and a macrocyclic DPTA derivative used in tumor pre-targeting strategies. It is applicable for the conjugation of peptides and radionuclides.

DOTATATE, a DOTA-conjugated peptide, is utilized for its ability to be labeled with radionuclides, facilitating positron emission tomography (PET) imaging and peptide receptor radionuclide therapy (PRRT)[4].

FAP-2286 acetate, a conjugate of a fibroblast activation protein (FAP)-binding peptide, exhibits antitumor activity [1]. It can be labeled with radionuclides for diagnostic purposes.

DOTA-Thiol is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative intended for tumor pretargeting. It is suitable for conjugation with peptides and radionuclides.

Deferoxamine-DBCO is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative employed in tumor pre-targeting. It is applicable for the conjugation of peptides and radionuclides.

DO2A-tert-butyl ester is a bifunctional chelator (Bifunctional Chelator; BFC) employed for the conjugation of peptides and radionuclides. It is useful in the development of imaging tracers for radionuclides.

Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs).

Butyne-DOTA is a bifunctional chelator (Bifunctional Chelator; BFC), serving as a macrocyclic DOTA derivative designed for tumor pre-targeting applications. It is utilized for the conjugation of peptides and radionuclides.

Azido-mono-amide-DOTA is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative designed for tumor pretargeting. It facilitates the conjugation of peptides and radionuclides.

DOTAM-mono-acid is a bifunctional chelator (BFC) and a macrocyclic DOTA derivative designed for tumor pre-targeting applications. It is suitable for conjugation with peptides and radionuclides.

DOTA-amide is a bifunctional chelator (Bifunctional Chelator; BFC) that serves as a macrocyclic DOTA derivative for tumor pretargeting. It's suitable for conjugation with peptides and radionuclides.